| 2025-02-07 | -0.9 % |
|
| 2025-02-04 | -0.07 % |
|
| 2025-02-03 | -1.48 % |
|
| 2025-01-23 | -0.16 % |
|
| 2025-01-21 | +0.27 % |
|
| 2025-01-16 | -0.6 % |
|
| 2025-01-14 | -0.07 % |
|
| 2025-01-13 | -3.17 % |
|
| 2025-01-06 | -0.5 % |
|
| 2024-12-31 | -0.28 % |
|
| 2024-12-17 | +0.28 % |
|
| 2024-12-16 | +0.8 % |
|
| 2024-12-12 | +0.22 % |
|
| 2024-12-10 | +3.51 % |
|
| 2024-12-06 | -1.24 % |
|
| 2024-12-05 | -2.39 % |
|
| 2024-12-04 | +5.7 % |
|
| 2024-12-03 | -0.47 % |
|
| 2024-12-02 | -1.15 % |
|
| 2024-11-29 | -1 % |
|
| 2024-11-27 | +0.73 % |
|
| 2024-11-26 | +0.39 % |
|
| 2024-11-25 | +1.12 % |
|
| 2024-11-22 | +0.14 % |
|
| 2024-11-21 | +1.21 % |
|
| 2024-11-20 | -0.94 % |
|
| 2024-11-19 | +0.44 % |
|
| 2024-11-18 | +3.14 % |
|
| 2024-11-13 | +1.08 % |
|
| 2024-11-07 | +0.14 % |
- Edwards Lifesciences (EW) stock rose by 0.14% amid mixed activity from institutional investors, with Robeco Institutional Asset Management significantly reducing its stake while others increased theirs, suggesting investor confidence in the company's long-term potential despite recent fluctuations.
The stock increase may be attributed to a combination of factors, including positive earnings results that met consensus estimates, growth in revenue compared to the previous year, and responses from analysts indicating a hold or buy rating, reflecting general optimism about the company's future prospects.
- Edwards Lifesciences (EW) stock was up 0.14% despite facing a class action lawsuit related to disappointing revenue guidance and performance for its TAVR platform, potentially indicating market optimism about recovery or interest in the company following recent negative news.
The stock may have gone up due to factors such as market recovery expectations, investor confidence in long-term growth, or speculative buying amidst the legal activity, despite the recent past decline related to the company's financial performance.
- The article discusses an investigation into Edwards Lifesciences Corporation regarding potential securities law violations, following a significant drop in their stock price due to disappointing financial results and reduced revenue guidance for their TAVR product, but despite this, the stock saw a slight increase of 0.14% last night.
The increase in Edwards Lifesciences (EW) stock may stem from investor reactions to potential recovery opportunities or market adjustments following the previous decline, as well as speculation regarding future performance and the overall health of the healthcare sector.
- Edwards Lifesciences (NYSE:EW) stock rose 0.14% following a significant insider sale of shares, but the overall market sentiment can be attributed to recent quarterly earnings results that met expectations and positive analyst upgrades despite some price target reductions.
- Edwards Lifesciences (EW) stock increased by 0.14% amid a class action lawsuit reminder for investors who suffered losses between February and July 2024, following a significant decline in stock price after disappointing fiscal results and lowered projections for its Transcatheter Aortic Valve Replacement (TAVR) platform.
The stock may have gone up due to short-term market recovery or investor speculation despite the ongoing legal issues and previous financial setbacks.
|
| 2024-11-05 | +0.33 % |
|
| 2024-11-04 | -1.58 % |
|
| 2024-11-01 | +0.79 % |
|
| 2024-10-31 | -2.36 % |
|
| 2024-10-30 | -1.07 % |
|
| 2024-10-29 | +1.24 % |
|
| 2024-10-28 | -1.24 % |
|
| 2024-10-25 | -1.38 % |
|
| 2024-10-24 | -0.37 % |
- Edwards Lifesciences (EW) stock experienced a decline of 0.37%, likely driven by broader market concerns, negative sentiment from foreign investor selling, and pressure from rising crude oil prices impacting overall market stability.
- Edwards Lifesciences (EW) stock declined by 0.37% despite Spectrum Asset Management significantly increasing its stake in the company by over 1,346% during the third quarter, possibly indicating mixed investor sentiment or broader market trends affecting the stock.
- Edwards Lifesciences (EW) stock fell by 0.37% after a mixed third-quarter report that showed missed sales expectations, primarily due to the exclusion of its recently divested critical care business, despite an increase in TAVR sales and adjusted earnings exceeding analyst predictions. The decline was driven by overall revenue that fell short of analysts' forecast, which led to concerns about the company's growth prospects.
- Edwards Lifesciences (EW) stock decreased by 0.37% due to broader market pressures, including a selling rush by foreign investors seeking better returns elsewhere, particularly in the Chinese market, which impacts overall investor sentiment.
- Edwards Lifesciences (EW) stock experienced a decline of 0.37% amidst a broader market focused on corporate earnings results and economic conditions, coupled with potential uncertainty surrounding the upcoming U.S. elections.
The stock's decline could be attributed to a combination of cautious investor sentiment in response to the overall market conditions, including potential headwinds from the elections and the impact of U.S. economic data.
|
| 2024-10-23 | +1.98 % |
- Edwards Lifesciences (EW) stock rose by 1.98% following Lecap Asset Management Ltd.'s recent acquisition of 61,831 shares, indicating institutional interest and confidence in the company.
- Edwards Lifesciences (EW) stock rose by 1.98% likely due to investor optimism following class action notifications regarding potential recovery opportunities for shareholders who experienced losses after the stock's significant decline in July, as well as ongoing interest in their TAVR platform despite previous financial setbacks.
- Edwards Lifesciences (EW) stock rose by 1.98% as institutional investors, including Blue Trust Inc. and Price T Rowe Associates, significantly increased their holdings in the company, indicating strong investor confidence in its future performance.
- The article discusses a securities fraud class action lawsuit filed against Edwards Lifesciences Corporation (EW) regarding misleading information provided to investors, coinciding with a recent 1.98% increase in the company's stock price, potentially attributed to improved investor sentiment following legal developments or stabilization after significant previous losses.
- Edwards Lifesciences Corporation's stock rose by 1.98%, despite facing a lawsuit alleging potential federal securities law violations, possibly due to investors responding positively to ongoing legal actions or speculation about the company's future prospects.
|
| 2024-10-22 | -1.16 % |
|
| 2024-10-21 | -0.31 % |
|
| 2024-10-18 | +2.63 % |
|
| 2024-10-17 | +0.25 % |
|
| 2024-10-16 | -0.87 % |
|
| 2024-10-15 | -1.05 % |
|
| 2024-10-14 | +2.2 % |
|
| 2024-10-11 | -0.19 % |
|
| 2024-10-08 | +6.2 % |
|
| 2024-10-07 | -1.45 % |
|
| 2024-10-04 | +0.18 % |
|
| 2024-10-03 | +0.34 % |
|
| 2024-10-02 | +0.08 % |
|
| 2024-10-01 | -1.35 % |
|
| 2024-09-27 | +1.23 % |
|
| 2024-09-25 | -1.39 % |
|
| 2024-09-24 | -1.53 % |
|
| 2024-09-17 | -3.07 % |
|
| 2024-09-13 | +0.57 % |
|
| 2024-08-13 | +1.24 % |
|